Blackstone to Fund Up to $1.5B of Pfizer's Monthly GLP-1 Obesity Drug Through 2028
PFE sits 25% above its 52-week low of $23.62.
Summary
Blackstone Life Sciences will pay up to $1.5 billion of development costs through 2028 for berobenatide, Pfizer's investigational monthly GLP-1 peptide for chronic weight management. Pfizer keeps full operational control and Blackstone gets no ownership in the drug; instead it earns milestone payments tied to US approval of monthly dosing and to commercial sales thresholds. The structure offloads a chunk of the obesity program's spend while keeping the upside in-house, which matters given the pipeline load: Pfizer plans 20+ obesity trials in 2026, including 10 Phase 3 studies of berobenatide. This builds on the Metsera acquisition that brought PF-3944 into the fold and follows the November 3rd guidance raise to $62.0-64.0 billion in revenue. The key question is whether berobenatide's monthly dosing holds up in Phase 3 and clears regulators, since the Blackstone payouts hinge on that approval and on sales milestones.
At the time of this announcement, PFE was trading at $29.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $167.9B. The 52-week trading range was $23.62 to $31.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.